Cell/Gene Tx channel feed

N-of-1 CRISPR tri­al ends with a death as non­prof­it digs in­to what hap­pened

3 years ago

Af­ter pulling IPO plans, Arti­va part­ners with Af­fimed to speed up NK cell ther­a­py com­bo

3 years ago
Deals
R&D

Al­lo­gene Over­land Bio­pharm com­pletes Shang­hai fa­cil­i­ty to man­u­fac­ture CAR-T prod­ucts

3 years ago
Pharma
Manufacturing

An NK cell ther­a­py biotech pulls IPO am­bi­tions weeks af­ter sec­ond tri­al clear­ance

3 years ago
Financing
Startups

ICER says it's fair for Bio­Marin and CSL to price in­com­ing he­mo­phil­ia gene ther­a­pies at $2M-$3M

3 years ago

Un­der hub-and-spoke biotech, se­r­i­al founders launch new start­up hop­ing to make gene ther­a­pies for the eye

3 years ago
Startups

A Dal­las biotech halts TIL ther­a­py tri­als — shares crater near­ly 30%

3 years ago
R&D

A biotech paused a gene ther­a­py hatched by fam­i­lies. Now they want con­trol

3 years ago
In Focus

Up­dat­ed: In broad re­treat, GSK's new R&D leader aban­dons NY-ESO plans, pulls plug on cell ther­a­py 2.0 al­liances af­ter los­ing faith

3 years ago
Deals

Pre­lude to buy­out? Astel­las picks up Taysha stock, two gene ther­a­py pro­grams for $50M

3 years ago
Deals

De­vel­op­ing gene ther­a­pies for neu­rode­gen­er­a­tive dis­eases: FDA fi­nal­izes guid­ance

3 years ago
FDA+

Scoop: Caris­ma stole CAR-M Thun­der for a while, but a Utah biotech is qui­et­ly rais­ing funds to en­ter the fray

3 years ago
Financing
Startups

UK reg­u­la­tor se­lects tiny Mass­a­chu­setts biotech's po­ten­tial Gauch­er gene ther­a­py for ac­cel­er­at­ed path­way

3 years ago

Up­dat­ed: Not known for gene ther­a­py plays, Eli Lil­ly ac­quires hear­ing loss start­up Ak­ou­os for $487M plus CVR

3 years ago
Deals

Lin­eage Cell Ther­a­peu­tics opens new Cal­i­for­nia R&D fa­cil­i­ty and ex­pands Is­rael man­u­fac­tur­ing site

3 years ago
Pharma
Manufacturing

New-look Fred Hutch snags slice of Be­zos for­tune for 10 years of re­search

3 years ago
People
Financing

Sang­amo gives an­oth­er up­date on ear­ly-stage Fab­ry pro­gram, en­ters tri­al ex­pan­sion phase

3 years ago
R&D

More ear­ly da­ta ma­nip­u­la­tion is­sues tied to No­var­tis block­buster as Na­ture re­tracts pa­per

3 years ago
R&D

Im­mat­ics spot­lights more ear­ly da­ta for TCR cell ther­a­py in sol­id tu­mors — now let's see if it lasts

3 years ago
R&D

CNS-fo­cused gene ther­a­py biotech forges man­u­fac­tur­ing deal for hear­ing loss drug

3 years ago
Deals
Manufacturing

Kite Phar­ma gets FDA to sign off on new Cal­i­for­nia-based vec­tor man­u­fac­tur­ing fa­cil­i­ty

3 years ago
Manufacturing

Af­ter 12 months of dig­ging, Pfiz­er opts for one of two Voy­ager cap­sids for gene ther­a­py

3 years ago
Deals

Am­pli­fy­Bio scoops up lab space and oth­er as­sets from PACT Phar­ma as cell ther­a­py biotech read­justs

3 years ago
Deals
Manufacturing

#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

3 years ago
R&D
Pharma
First page Previous page 24252627282930 Next page Last page
A service from the Financial Times